Wegovy 0.5mg: the second step on the titration ladder

You're four weeks in, pen two is in the fridge, here's where you stand

You started at 0.25mg because that first month is about settling in, not losing weight at pace. Semaglutide slows the stomach, damps appetite signals and changes how satisfying food feels, and all of that takes adjustment. By the time you open your 0.5mg Wegovy pen, your body has had four weeks to find its footing.

At this dose you are still in what the NHS medicines guidance for semaglutide describes as the escalation phase. The 0.5mg step typically lasts another four weeks, after which most people move to 1mg, and that is where the licensed titration schedule picks up speed through 1.7mg toward the 2.4mg maintenance dose. Some people stay at 0.5mg a little longer if nausea or other gastrointestinal symptoms haven't fully settled. That is a clinical decision, not a sign that something has gone wrong.

If you want to understand how all five steps fit together, the full picture is covered on our Wegovy dosing overview. The short version: 0.5mg is a bridge, not a destination.

One practical note, if you collect or receive a new pen on a Monday, the 12pm cut-off for same-day dispatch means timing your injection day sensibly avoids any unnecessary gap.

What side effects are most common at this stage?

The side-effect profile at 0.5mg looks much like 0.25mg, though some people find they notice GI symptoms a little more as the dose steps up. Nausea is the most frequently reported; loose stools, constipation, indigestion and feeling full unusually quickly are also common. Fatigue, headache and mild dizziness appear in some people, particularly early on.

These effects tend to be most noticeable in the first few days after moving to the new dose, then ease as the body adapts. Eating smaller portions, avoiding high-fat foods and staying well hydrated are the practical recommendations most prescribers give during titration, details that sit in your Patient Information Leaflet and are worth re-reading at each step.

Serious side effects are uncommon but worth knowing. Severe, persistent stomach pain (especially pain that radiates toward the back) should prompt urgent medical attention; the MHRA has flagged acute pancreatitis as a rare but serious risk with GLP-1 medicines and issued a formal Drug Safety Update on this in January 2026. Any suspected side effects can be reported to the MHRA's Yellow Card scheme.

If you are comparing how the 0.5mg experience sits against the next step, there is more detail on the Wegovy 5mg page, though the standard schedule reaches 1mg before 1.7mg, so that dose-by-dose context is worth reading in order.

When does 0.5mg Wegovy actually start working for weight loss?

Honestly, many people feel some early appetite change at 0.5mg, reduced interest in snacking, feeling full on less. But meaningful weight loss in clinical trials built across the full titration period, with the 2.4mg maintenance dose producing the landmark results. The STEP 1 trial published in the New England Journal of Medicine reported around 15% average body-weight reduction over 68 weeks at 2.4mg, a figure accumulated from the whole treatment course, not just the maintenance phase.

That framing matters. Expecting dramatic results at 0.5mg sets an unfair baseline. The dose's purpose is tolerance and safety, not speed. People who push through titration faster than their prescriber recommends tend to experience worse side effects, which can lead to stopping treatment altogether, which serves nobody.

The Wegovy treatment overview covers the full evidence picture, including how results vary between individuals and what the clinical trials actually measured. For context on what private treatment involves, our Wegovy price comparison page explains what to look for when assessing the true cost of supervised treatment in the UK.

If you are already on treatment and want to discuss your progress at this dose, our support team is available seven days a week.

Who decides the pace, and what if 0.5mg isn't right for you?

The titration schedule in the Wegovy SmPC is a framework, not a rulebook. Prescribers have clinical reasons to hold at a dose, reduce back temporarily or occasionally skip ahead. Common reasons to stay at 0.5mg longer include persistent nausea, vomiting that is disrupting daily life or a recent illness that has already put the gut under stress.

Reducing back to 0.25mg after side effects at 0.5mg is also possible, though always a prescriber call, not something to do based on online advice. The Patient Information Leaflet sets out what to do with missed doses; if in doubt, the rule is always: ask your prescriber rather than guess.

People sometimes arrive at 0.5mg semaglutide having transferred from another service or another GLP-1 medicine. If that is your situation, the clinical review at transfer checks your history and current dose before anything changes. Detailed questions about how the process works are addressed in our FAQs, and the full clinical team background is there if you want to know who reviews your case.

If you are not yet on Wegovy and are wondering whether you might be eligible, a free consultation with our prescribers is the right first step. Check your eligibility and a GPhC-registered Independent Prescriber will review your case the same day.